Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Is thrombin-activatable fibrinolysis inhibitor antigen (TAFIag) level significant in recurrent miscarriage?
Show Less
1
Zeynep Kamil Training and Research Hospital, Department of Obstetrics and Gynecology, Istanbul
2
Derince Training and Research Hospital, Department of Obstetrics and Gynecology, Kocaeli (Turkey)
3
Dr. Lutfi Kırdar Kartal Training and Research Hospital, Department of Biochemistry, Istanbul
Clin. Exp. Obstet. Gynecol. 2014, 41(4), 448–450;
https://doi.org/10.12891/ceog17352014
Published: 10 August 2014
Abstract
Objective: The aim of this study was to evaluate the plasma thrombin-tat fibrinolysis inhibitor antigen (TAFIag) levels in women with recurrent miscarriage (RM) and age-matched healthy parous women as controls. Materials and Methods: A total of 80 patients were enrolled in this study. As a study group (group 1), the authors evaluated 49 RM patients who had two or more consecutive abortions with unknown etiology before 12 weeks of gestation. The remaining 31 patients (group 2) were age-matched healthy parous women with no history of miscarriage and experienced at least one live baby. Results: Comparisons of blood TAFIag levels revealed no statistically significant difference between women with recurrent miscarriages and control group. Conclusions: The findings of the present study indicated that TAFIag level was not associated with recurrent miscarriages.
Keywords
Thrombin-activatable fibrinolysis inhibitor
Recurrent miscarriage
Unknown etiology